The high frequency of cancer-associated genetic alterations causing constitutive activation of PI3K-AKT and RAF-MEK-ERK and the addiction of cancer cells to their signals have led to enthusiasm for developing inhibitors of these pathways. The gene discussed is MAP2K7; the disease is cancer.